Medulloblastoma, treatment outcome and prognostic factors at National cancer institute, Egypt 2008-2013 / Ahmed Mustafa Abdelsalam ; Supervised Emad Nabil Ebeid , Nesreen Ali Ahmed , Reem Mohamed Emad Eldin

Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology

Purpose: Medulloblastoma (MB) is the most common malignant brain tumor of childhood. It occurs at all ages, peaking in incidence between 4 and 7 years. Our aim was to assess the outcome and prognostic factors among MB pediatric patients at the National cancer institute, Cairo university. Methods: This is a retrospective study included 53 eligible patients with established diagnosis of medulloblastoma during the period from January 2008 to December 2013. Results: Among the 53 patients, 31 were males (58.5%). Median age at diagnosis was 6 years (range 0.6-18 years). Vomiting was the most frequent presenting symptom followed by headache detected in 90.6% and 86.8% of patients, respectively. The majority of our patients were high risk 45 patients (84.9%) (15% of them infantile {u2264}3 years), while 8 patients (15.1%) were standard risk. Median follow up period was 38.6 months (range 13.3 to 81.9). The 5-year overall survival (OS) and disease-free survival (DFS) rates were 54.6% and 74.8%, respectively. The presence of postoperative residual, spinal seedling, M staging, and completing chemotherapy protocol had a significant difference regarding survival rate (p=0.045, p<0.001, p=0.021 and p<0.001, respectively). There was no significant difference between patients presented at age {u2264}3 years versus >3 years old regarding survival rate (5-year OS 50.0% versus 55.2%, respectively), also histopathological subtypes had no impact on survival (p=0.099). At the end of this study 29 patients (54.7%) were alive, 22 patients (41.5%) were dead and 2 patients (3.8%) lost follow up. Two out of 53 patients relapsed after treatment

Issued also as CD